This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

FibroGen anemia patent revoked, Teva and Sandoz pave way for generic drug

By Inbar Preiss ( March 28, 2025, 11:59 GMT | Insight) -- Teva and Sandoz have successfully challenged FibroGen’s European patent on the anti-anemia drug roxadustat at the European Patent Office, clearing the way for generic alternatives in the EU. The Technical Board of Appeal ruled that FibroGen’s formulation lacked an inventive step. The ruling overturns a prior decision that upheld the patent in amended form and confirms that photostability testing is a routine industry practice.Teva Pharmaceutical Industries Ltd. and Sandoz AG have secured a victory in their challenge to FibroGen’s European patent on the anti-anemia drug Roxadustat, effectively clearing the way for generic versions in the EU....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections